Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort
BIC/FTC/TAF demonstrated high persistence, safety, virological efficacy, and favorable metabolic profile over 48 weeks. The cross-sectional survey indicated high treatment satisfaction and good quality of life in this cohort from Argentina.
Authors
- Diego Cecchini (ORCID: https://orcid.org/0000-0002-8545-6132)
- Maura Seleme (ORCID: https://orcid.org/0000-0002-4444-6333)
- Martín Brizuela (ORCID: https://orcid.org/0000-0003-2113-449X)
- G Copertari
- Romina Mauas
- Edgardo Bottaro (ORCID: https://orcid.org/0009-0001-0602-5175)
- Isabel Cassetti (ORCID: https://orcid.org/0009-0003-4399-2628)
- B Bacelar
- M V Mingrone
Institutions
- Helios Salud (AR)
Publication Details
- Journal
- Revista Española de Quimioterapia
- Published
- 2024-11-20
- DOI
- https://doi.org/10.37201/req/080.2024
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences